{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-75.30","upperLimit":"31.48","value":"-15.90"},{"groupId":"OG001","lowerLimit":"-100.00","upperLimit":"51.10","value":"-24.60"},{"groupId":"OG002","lowerLimit":"-87.5","upperLimit":"32.4","value":"-14.3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"32"},{"groupId":"OG001","value":"32"},{"groupId":"OG002","value":"33"}],"units":"Participants"}],"description":"The percentage change (reduction) from baseline in the sum of the lengths of the longest diameter (LD) of the RECIST target lesions were objectively documented, regardless of whether the patient was still taking study medication","dispersionType":"Full Range","groups":[{"description":"Olaparib (AZD2281) 200 mg oral capsules twice daily","id":"OG000","title":"Olaparib 200 mg bd"},{"description":"Olaparib (AZD2281) 400 mg oral capsules twice daily","id":"OG001","title":"Olaparib 400 mg bd"},{"description":"Liposomal doxorubicin 50 mg/m2 intravenously every 4 weeks","id":"OG002","title":"Liposomal Doxorubicin"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"At the time that 57 PFS events had occurred (Data cut-off for primary analysis of PFS: 15 September 2009)","title":"Best Percentage Change in Tumour Size","type":"SECONDARY","unitOfMeasure":"Percent change"}